Navigation Links
Columbia awarded 1 of first 'Provocative Questions' grants from NCI
Date:9/19/2012

New York, NY (September 20, 2012) Columbia University Medical Center (CUMC) is one of 50 institutions selected nationwide from more than 700 applications for a "Provocative Questions" grant from the National Cancer Institute (NCI). In a departure from its traditional grant-making process, NCI solicited research proposals related to 24 questions that could lead to significant advances in cancer research. These grants represent new and different ways to identify and address research needs in cancer.

Timothy H. Bestor, PhD, an epigenetics researcher and professor of genetics and development at CUMC, was selected for his proposal, "Methylation Suicide in Cancer," which could overturn a theory of carcinogenesis that has stood for more than 20 years.

Methylation is a chemical modification of DNA that can turn genes off without altering DNA sequence. Cells use DNA methylation to lock genes in the "off" position.

Since the 1980s, scientists have thought that DNA methylation of tumor suppressor genes is a key event in carcinogenesis, driving cells to become cancer cells. However, when Dr. Bestor and his team tried to find examples of tumor progression driven by methylation (with the eventual goal of being able to turn off this methylation), they were unable to find any, either in their laboratory research on breast cancer tissue or through a literature review. This led them to an alternative hypothesis of "methylation suicide," in which methylation changes are part of the normal pathways that kill incipient cancer cells. Dr. Bestor's NCI grant supports the study of this hypothesis.

"We expect that our research will cause people to question scientific dogma, which is always good," said Dr. Bestor, who is also a member of the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian Hospital/CUMC. "Our hypothesis is one of the first alternatives to the methylation carcinogenesis model, which has gone unchallenged and untested for more than 20 years.

"If our methylation suicide in cancer hypothesis is correct, then our teamas well as other research teams around the worldcan start looking for drugs to enhance the response, make it go off even more and kill more cancer cells," said Dr. Bestor. "We hope to publish our findings soon."

The question associated with Dr. Bestor's research is whether new methods can be developed to discriminate between "driver" and "passenger" epigenetic events, as scientists are better able to identify epigenetic changes that occur during tumor development. Epigenetic events are mechanisms that change patterns of gene expression without affecting the DNA sequence. These changes can persist through cell division and can be passed from parent to offspring.

In short, Dr. Bestor will aim to address is whether new hypotheses can lead to methods to differentiate between events that initiate carcinogenesis versus those that carry it along.

NCI's Provocative Questions project emerged from discussion among veteran cancer researchers. There were a number of questionssome important but not obvious, some that had been asked but abandoned because researchers lacked ways to address them, some sparked by new discoveries or novel technologiesthat they believed could stimulate the NCI's research communities to use laboratory, clinical, and population sciences in especially effective and imaginative ways.

Over a period of 18 months, NCI solicited questions from scientists in various fields and at different stages in their careers, ultimately settling on 24 questions that, if answered, could lead to significant research advances.


'/>"/>
Contact: Elizabeth Streich
estreich@columbia.edu
212-305-3689
Columbia University Medical Center
Source:Eurekalert

Related biology news :

1. Winemaking goes high-tech at the University of British Columbia
2. Scientists reconstruct pre-Columbian human effects on the Amazon Basin
3. Forensic science used to determine whos who in pre-Columbian Peru
4. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
5. Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering
6. Rockefeller Universitys Pearl Meister Greengard Prize to be awarded to RNA researcher Joan Steitz
7. Yale Universitys Joan Steitz awarded 2012 Vanderbilt Prize
8. University of Illinois at Urbana-Champaign awarded 5-year grant from NASA
9. Georgetown Lombardi researcher awarded Provocative Question grant from NCI
10. 6 NARSAD Young Investigator Grants awarded to CAMH
11. ASU awarded $3 million to research solar energy technologies, launch energy Ph.D. program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems ... seamlessly log work hours, for employers to make sure the right employees are actually ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/3/2016)... LONDON , June 3, 2016 /PRNewswire/ ... Transport Management) von Nepal ... ,Angebot und Lieferung hochsicherer geprägter Kennzeichen, einschließlich ... weltweit führend in der Produktion und Implementierung ... an der Ausschreibung im Januar teilgenommen, aber ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology: